Remove Diabetes Remove Labelling Remove Research Laboratories
article thumbnail

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

This asset has potential applications in diabetic macular oedema (DME) and neovascular age-related macular degeneration (NVAMD). The acquisition includes EyeBio’s lead asset Restoret (EYE-103), a tetravalent, tri-specific antibody that targets the Wingless-related integration site (Wnt) signalling pathway.